Helius Kicks Off $500M Solana Treasury with 760,190 SOL Acquisition
Helius Medical Technologies, Inc. (NASDAQ: HSDT)has kick-begined its accumulation sprint with the of an initial purchase of 760,190 at an average cost basis of $231 per token. The company also has more than $335 million in cash set aside for future acquisitions as part of its long-term financial strategy.
Helius describes the move as a shift towards using SOL as its principal reserve asset, indicating confidence in Solana’s growth, staking income, and ecosystem adoption. The acquisition is consistent with the wider company goal of increasing shareholder value by using while maintaining its neurotech and medical device operations.
Helius is pivoting its capital markets focus to maximize shareholder value via opportunistic . Cosmo Jiang, Pantera Capital general partner and Helius board observer, emphasized how “laser focused the team is on maximizing shareholder value by having market awareness and being responsible stewards of capital.”
Investor Takeaway
Helius is betting large on Solana as it kickbegins its $500M Solana treasury strategy with a 760,190 SOL purchase. The company has positioned SOL as its primary reserve asset to drive shareholder value beyond its core medical business.
Helius Votes ‘Yield-Bearing’ Solana as Treasury Asset
Helius’ announcement follows a private investment in public equity (PIPE) financing spearheaded by and Summer Capital, as well as other institutional and crypto-native investors, earlier in September. The funds obtained in that round serve as the financial foundation for the Solana treasury initiative.
Helius’ theory is supported by the Solana network’s fundamentals, which include a high throughput of over 3,500 transactions per second, about 3.7 million daily active wallets, and more than 23 billion transactions recorded so far. SOL also pays out approximately 7% in , providing a yield edge over non-yield-bearing assets such as .
Executive chairman Joseph Chee said, “We take our responsibility to maximize shareholder value seriously and are eager to execute against our plan.” He emphasised the importance of long-term confidence and stakeholder alignment within the Solana ecosystem through strategic collaborations with staking providers and .
Helius joins a wave of listed firms transitioning from cash-heavy reserves to actively managed, yield-bearing digital assets through its Solana treasury. The company will continue to scale its neurotech and medical products business alongside digital network holdings.
Investor Takeaway
Broader Solana Treasury Outlook
Helius’ Solana treasury move follows similar Solana accumulation by forward-looking treasuries such as , , , and Upexi, and signals the emergence of SOL as an institutional secure haven for capital-efficient on-chain yield. With over $335 million still unspent, Helius plans to accumulate further as new entry opportunities arise.
Though the Solana acquisition represents the begin of Helius’ treasury accumulation, the company remains operationally focused on its core business areas of neuromodulation and medical devices. The dual approach attempts to strike a balance between innovation in digital assets and long-term development in its medical technology sectors.
